{"id":"W4410455677","doi":"10.1016/j.esmoop.2025.104985","title":"414TiP Phase I/II study (Duravelo-1) of zelenectide pevedotin, a Bicycle Toxin Conjugate: Additional cohort (B-8) in patients with advanced breast cancer","year":2025,"lang":"en","type":"article","venue":"ESMO Open","topic":"Radiopharmaceutical Chemistry and Applications","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"ca_institutions":"","funders":"Cilag; University of Texas MD Anderson Cancer Center; EMD Serono; Daiichi Sankyo Europe; Servier; Genentech; Institut Gustave-Roussy; European Society for Medical Oncology; Basilea Pharmaceutica; Astellas Pharma; Eisai; Plexxikon; Seagen; Bayer HealthCare; G1 Therapeutics; Chugai Pharmaceutical; NGM Biopharmaceuticals; Incyte; Boston Pharmaceuticals; Agios Pharmaceuticals; Syndax Pharmaceuticals; Eisai Canada; Cholangiocarcinoma Foundation; BeiGene; Clovis Oncology; Loxo Oncology; Astex Pharmaceuticals; Les Laboratories Pierre Fabre; Centre Léon Bérard; MacroGenics; Celldex Therapeutics; Sanofi; Exelixis; Array BioPharma; Jazz Pharmaceuticals; National Institutes of Health; Regeneron Pharmaceuticals; Merck KGaA; Celgene; Carrick Therapeutics; AstraZeneca; Ignyta; Eli Lilly and Company; Bristol-Myers Squibb; Amgen","keywords":"Breast cancer; Conjugate; Cohort; Toxin; Medicine; Oncology; Internal medicine; Cancer; Microbiology; Biology; Mathematics","routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0001085143,0.000135951,0.0003269029,0.00005134206,0.00009313416,0.00001329337,0.0002090859,0.00004107191,0.003433895],"category_scores_gemma":[0.00004604433,0.0001141802,0.0000284401,0.000429096,0.00008103747,0.0001117538,0.0001167508,0.0001861643,0.000005840058],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001010676,"about_ca_system_score_gemma":0.0002555221,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0003013077,"about_ca_topic_score_gemma":0.0000984295,"domain_scores_codex":[0.9989641,0.00002604006,0.0003066094,0.0003198826,0.0002068899,0.0001764525],"domain_scores_gemma":[0.9993065,0.00007033155,0.00008690211,0.0002689687,0.0001673995,0.00009992671],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.00475774,0.01112518,0.962773,0.0001002356,0.0003582074,0.00001643477,0.0001450741,0.0000660895,0.002658438,0.0001573034,0.006517801,0.01132446],"study_design_scores_gemma":[0.01493603,0.0004393721,0.9659402,0.0002630458,0.0001171373,0.000003529585,0.0001202879,0.00005213837,0.01525983,0.00003482649,0.002705143,0.0001284737],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.990977,0.00001194355,0.000007618499,0.001074973,0.00002414712,0.001916774,0.001075593,0.0000159454,0.004895979],"genre_scores_gemma":[0.9969192,0.000004991693,0.0002194892,0.000382426,0.0000247916,0.0008260141,0.0004094282,0.00001202938,0.001201655],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.01260139,"threshold_uncertainty_score":0.9974771,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01195093419835612,"score_gpt":0.3557951380520973,"score_spread":0.3438442038537412,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}